FDA accepts Alkermes application for ALKS 383

The FDA accepts for review Alkermes plc’s (NASDAQ:ALKS) marketing application seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and bipolar I disorder. The agency’s action date is November 15.

Shares up 4% premarket on light volume.

https://seekingalpha.com/news/3535046-fda-accepts-alkermes-application-for-alks-3831-shares-ahead-4-premarket